FY March 2026 Q3 Financial Summary [IFRS] (Consolidated)

Performance Overview

For the third quarter of the fiscal year ending March 2026, consolidated revenue was JPY 210.8 billion, down 5.4% year-over-year, operating income was JPY 28.2 billion, down 19.8%, and net income attributable to owners of the parent for the quarter was JPY 21.8 billion, down 20.6%. The results were affected by drug price revisions and inventory adjustments in distribution channels; however, efforts focusing on new and core products resulted in progress in line with the full-year forecast. Regionally, Japan declined by 12.4%, China was roughly flat YoY, while Asia excluding China and EMEA showed growth trends. R&D expenses increased by 9.5% YoY, and amortization of intangible assets related to products remained nearly flat compared with the previous year.

Financial Position and Cash Flow Status

At the end of the third quarter, total assets amounted to JPY 401.2 billion, decreasing compared to the previous year, total equity was virtually unchanged at JPY 282.4 billion, liabilities decreased to JPY 118.7 billion, and the equity ratio attributable to owners of the parent rose by 0.7 points to 70.6%. Cash flow from operating activities was an inflow of JPY 22.5 billion, down compared to the previous year. Cash outflows from investing activities totaled JPY 11.6 billion and financing activities outflowed JPY 47.8 billion. The reduction in shares outstanding due to treasury stock retirement affected basic earnings per share, but there is no change to the dividend forecast.